Pulmonology Medical News about Economic Costs

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Economic Costs of Undiagnosed Diabetes
Population Health Management, 04/27/09

Zhang Y et al. - The estimated economic costs of UDM in 2007 is $18 billion ($2864 per person with UDM), including medical costs of $11 billion and indirect costs of $7 billion. Although the high prevalence of UDM makes it an important health issue to be studied, data limitations have contributed to a dearth of information on the health care use patterns and economic costs of UDM. By omitting UDM, estimates of the total national cost of diabetes are underestimated.

<< Previous
Faster Radioiodine Washout in the Treatment of Pulmonary...

Next >>
Does income-related health inequality change as the population...

The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios: Results across Five Trial-Based Cost-Utility Studies
Value in Health, 11/11/09 Relevance Score: 68%

Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation
Annals of Internal Medicine, 11/04/09 Relevance Score: 68%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09 Relevance Score: 67%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09 Relevance Score: 67%

Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09 Relevance Score: 67%